Narayana Hrudayalaya
- Market Cap
- ₹39,722 Cr
- P/E
- 46.25
Key Fundamentals
MidcapHealthcare ServicesHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 15.50%
- Debt to Equity
- 1.21
- EPS (TTM)
- ₹42.03
- Book Value
- ₹244.81
- Market Cap
- ₹39,722 Cr
- P/E (TTM)
- 46.25
- P/B
- 7.94
- ROE
- 20.50%
- Dividend Yield
- 0.24%
- EBITDA
- ₹1,717 Cr
- 52W High
- ₹2,092.90
- 52W Low
- ₹1,589.00
- Day Range
- ₹1,868.00 – ₹1,960.00
- Volume
- 7,84,702
Peer Comparison
Healthcare › Healthcare Services › Hospital
| 9,200.00 | 59.00 | 1,32,282 | 12.47 | 0.23% | 21.50% | 17.40% | 27,630 | 2,337 | |
| 1,081.00 | 76.23 | 1,05,215 | 9.28 | 0.20% | 14.70% | 14.70% | 9,146 | 1,380 | |
| 702.20 | 101.77 | 92,366 | 6.01 | 0.00% | 6.72% | 8.30% | 12,370 | 873 | |
| 779.30 | 110.70 | 67,929 | 8.72 | 0.41% | 11.30% | 11.60% | 6,508 | 564 | |
| 825.00 | 59.96 | 62,284 | 5.94 | 0.13% | 11.20% | 13.40% | 9,910 | 1,061 | |
| 1,480.20 | 64.33 | 39,798 | 9.20 | 0.03% | 15.20% | 17.40% | 5,053 | 613 | |
| 1,943.70 | 46.25 | 39,722 | 7.94 | 0.24% | 20.50% | 15.50% | 10,273 | 859 | |
| Median 7 companies | 1,081.00 | 64.33 | 67,929 | 8.72 | 0.20% | 14.70% | 14.70% | 9,910 | 873 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 62
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 59
- Good
- Cheap vs sector & own history 24% weight
- Growth
- 99
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 17
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 19
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 57
- Good
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is expected to give good quarter
- Company has a good return on equity (ROE) track record: 3 Years ROE 24.5%
Weaknesses
1- Stock is trading at 7.94 times its book value
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 1 | 6 | 12 |
| Oscillators | Bullish | 1 | 6 | 2 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Bullish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 63.53
- Neutral
- MACD (12,26,9)
- 35.03
- Bullish
- SMA (50)
- 1,811.53
- Bullish
- SMA (200)
- 1,841.52
- Bullish
As of
Analyst Rating
9 of 10 analysts rate Buy, 1 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +17.21% |
|---|---|
| 5Y | +25.04% |
| 3Y | +20.39% |
| 1Y | +44.01% |
| TTM | +72.34% |
Net profit
| 10Y | +44.02% |
|---|---|
| 5Y | Turned to profit |
| 3Y | +9.91% |
| 1Y | +1.90% |
| TTM | +1.66% |
Operating cash flow
| 10Y | +25.00% |
|---|---|
| 5Y | +39.76% |
| 3Y | +14.32% |
| 1Y | +64.40% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +9.63 pp |
|---|---|
| 5Y | +13.46 pp |
| 3Y | −1.03 pp |
| 1Y | −2.89 pp |
| TTM | −5.12 pp |
Revenue by year
| Mar 2017 | ₹1,878 Cr |
|---|---|
| Mar 2018 | ₹2,281 Cr |
| Mar 2019 | ₹2,861 Cr |
| Mar 2020 | ₹3,128 Cr |
| Mar 2021 | ₹2,583 Cr |
| Mar 2022 | ₹3,701 Cr |
| Mar 2023 | ₹4,525 Cr |
| Mar 2024 | ₹4,890 Cr |
| Mar 2025 | ₹5,483 Cr |
| Mar 2026 | ₹7,896 Cr |
Net profit by year
| Mar 2017 | ₹83.00 Cr |
|---|---|
| Mar 2018 | ₹51.00 Cr |
| Mar 2019 | ₹59.00 Cr |
| Mar 2020 | ₹119 Cr |
| Mar 2021 | −₹14.00 Cr |
| Mar 2022 | ₹342 Cr |
| Mar 2023 | ₹607 Cr |
| Mar 2024 | ₹790 Cr |
| Mar 2025 | ₹791 Cr |
| Mar 2026 | ₹806 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Narayana Hrudayalaya trades at ₹1,907.6 as of 2026-11-17 with a market cap of ₹38,984 Cr, a P/E of 45.39x, and a price-to-book of 7.79x. The company has delivered strong long-term revenue and profit compounding but recent TTM profit growth has moderated to 6%, while debt-to-equity stands at 1.29.
- Compounded sales growth of 17% over 10 years and 20% over 3 years demonstrates consistent revenue expansion in a structurally growing healthcare market
- 5-year compounded profit growth of 155% reflects a dramatic improvement in profitability and operating leverage over a meaningful period
- ROE of 17.85% as of 2026-11-17, backed by a 3-year average ROE of 25% and 5-year average of 26%, signals strong and sustained capital efficiency
- TTM revenue growth of 72% indicates a significant acceleration in top-line momentum in the most recent period
- Stock price CAGR of 26% over 5 years and 19% over 10 years shows long-term wealth creation for shareholders
- Company is expected to deliver a good upcoming quarter, suggesting near-term operational momentum remains intact
- 10-year compounded profit growth of 42% highlights the company's ability to scale earnings over a full business cycle
- Price-to-book ratio of 7.79x is high, meaning investors are paying a steep premium over the company's net asset value
- Debt-to-equity ratio of 1.29 indicates meaningful leverage on the balance sheet, which increases financial risk in a rising interest rate environment
- TTM profit growth has decelerated sharply to 6% compared to 5-year compounded profit growth of 155%, suggesting the earnings growth trajectory may be normalising
- Dividend yield of just 0.24% offers negligible income return, making shareholders almost entirely dependent on capital appreciation
- 1-year stock CAGR of -2% shows the stock has underperformed over the recent 12-month period despite revenue acceleration
- ROCE of 11.39% trails ROE of 17.85%, partly reflecting the impact of debt in the capital structure and suggesting returns on total capital employed are more modest
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Narayana Hrudayalaya delivered a strong Q2FY27 with 16.5% profit growth and impressive India hospital margin expansion to 26.8%. The underlying India and Cayman businesses are performing well, with international patient revenue surging 76% and a robust 1,555-bed expansion pipeline on track. The key risk is the UK business, which is loss-making and dragging down consolidated margins to 19.5% from 24.5%. If the UK turnaround gains traction and India momentum sustains, the trend remains firmly positive heading into H2FY27.
- UK business loss widens Oct 30
UK revenue fell 0.9% sequentially to £64.4 million with a net loss of £2.7 million in Q2FY27, up from £2.2 million loss in Q1FY27. EBITDA margin stood at just 7.2%.
- EBITDA margin contracts on consolidation Oct 30
Consolidated EBITDA margin contracted to 19.5% from 24.5% YoY, largely due to the lower-margin UK business dragging down the blended figure.
- Net debt at ₹1,883 crore Oct 30
Net debt stood at ₹1,883 crore as of Sep 30, 2026 with a net debt-to-equity ratio of 0.38, reflecting the capital deployed for the UK acquisition and expansion projects.
- Q2 profit surges 16.5% YoY Oct 30
Consolidated net profit rose 16.5% YoY to ₹301 crore in Q2FY27, with PAT up 45.3% sequentially. Revenue surged 73% YoY to ₹2,844 crore.
- India margins expand strongly Oct 30
India hospital EBITDA margin expanded to 26.8% from 23.8% YoY, aided by lower doctor/nurse costs (25.9% vs 26.7%) and lower consumables (22.2% vs 23.4%).
- International patient revenue up 76% Oct 30
International patient revenue surged 75.7% YoY and 41.2% sequentially to ₹90.1 crore, now contributing 7% of India hospital revenue.
- NCLT approves demerger scheme Nov 4
NCLT Bengaluru sanctioned the demerger of NH Integrated Care's clinical services into Narayana Hrudayalaya effective Apr 1, 2025. No shares were issued as consideration.
- Investor meetings Nov 18-19 Nov 17
Narayana Health will hold one-to-one physical meetings with institutional investors including IMCO and Wasatch Global Advisors on Nov 18-19, 2026.
- New statutory auditors appointed Oct 30
Board recommended B S R & Co. LLP as statutory auditors for five years from 2027 AGM, replacing Deloitte Haskins & Sells LLP.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,305 | 1,204 | 1,246 | 1,306 | 1,367 | 1,335 | 1,475 | 1,507 | 1,644 | 2,151 | 2,594 | 2,684 | 2,844 |
| Expenses | 997 | 925 | 955 | 1,004 | 1,058 | 1,027 | 1,118 | 1,171 | 1,243 | 1,786 | 2,086 | 2,216 | 2,293 |
| Operating Profit | 308 | 279 | 291 | 302 | 309 | 307 | 358 | 337 | 401 | 365 | 508 | 468 | 551 |
| OPM % | 24% | 23% | 23% | 23% | 23% | 23% | 24% | 22% | 24% | 17% | 20% | 17% | 19% |
| Other Income | 18 | 18 | 26 | 24 | 23.6 | 18 | 20 | 24 | 24 | −29 | 25 | 35 | 51.54 |
| Interest | 23 | 25 | 28 | 34 | 35 | 37 | 41 | 45 | 42 | 65 | 91 | 87 | 96.72 |
| Depreciation | 55 | 63 | 65 | 61 | 65 | 70 | 82 | 84 | 87 | 122 | 154 | 156 | 163 |
| PBT | 248 | 209 | 226 | 231 | 232 | 219 | 254 | 231 | 297 | 149 | 288 | 260 | 343 |
| Tax % | 9% | 10% | 15% | 13% | 14% | 12% | 22% | 15% | 13% | 15% | 22% | 20% | 12% |
| Net Profit | 227 | 188 | 191 | 202 | 199 | 193 | 197 | 197 | 258 | 127 | 224 | 207 | 301 |
| EPS (₹) | 11.09 | 9.20 | 9.33 | 9.85 | 9.72 | 9.44 | 9.65 | 9.62 | 12.64 | 6.20 | 10.96 | 10.14 | 14.73 |
| YoY Sales growth | 14 | 7 | 2 | 6 | 5 | 11 | 18 | 15 | 20 | 61 | 76 | 78 | 73 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,364 | 1,614 | 1,878 | 2,281 | 2,861 | 3,128 | 2,582 | 3,701 | 4,525 | 4,890 | 5,483 | 7,896 | 10,273 |
| Expenses | 1,236 | 1,434 | 1,642 | 2,064 | 2,566 | 2,694 | 2,394 | 3,038 | 3,538 | 3,722 | 4,185 | 6,255 | 8,380 |
| Operating Profit | 128 | 180 | 236 | 217 | 295 | 434 | 189 | 664 | 987 | 1,168 | 1,298 | 1,641 | 1,893 |
| OPM % | 9% | 11% | 13% | 10% | 10% | 14% | 7% | 18% | 22% | 24% | 24% | 21% | 18% |
| Other Income | 6 | −19 | 7 | 18.9 | 16.67 | 7 | 28.18 | 34.56 | 59 | 75.19 | 80 | 37 | 83 |
| Interest | 45 | 33 | 28 | 55 | 81 | 94 | 82 | 76 | 84 | 112 | 163 | 266 | 340 |
| Depreciation | 68 | 76 | 80 | 100 | 137 | 186 | 184 | 183 | 210 | 242 | 278 | 448 | 595 |
| Exceptional Items | — | — | — | — | — | — | −6.84 | −8.53 | — | — | — | — | — |
| PBT | 21 | 51 | 135 | 80 | 93 | 161 | −56 | 430 | 752 | 889 | 936 | 964 | 1,041 |
| Tax % | 71% | 59% | 39% | 36% | 37% | 26% | −75% | 20% | 19% | 11% | 16% | 16% | — |
| Net Profit | −19 | 21 | 83 | 51 | 59 | 119 | −14 | 342 | 607 | 790 | 791 | 806 | 859 |
| EPS (₹) | −0.84 | 1.04 | 4.06 | 2.51 | 2.90 | 5.82 | −0.70 | 16.73 | 29.67 | 38.62 | 38.66 | 39.42 | 42.03 |
| Div. Payout % | 0% | 0% | 0% | 0% | 35% | 17% | 0% | 6% | 8% | 10% | 12% | 11% | — |
| Sales growth | 25 | 18 | 16 | 21 | 25 | 9 | −17 | 43 | 22 | 8 | 12 | 44 | 72 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 200 | 204 | 204 | 204 | 204 | 204 | 204 | 204 | 204 | 204 | 204 | 204 | 204 |
| Reserves | 568 | 672 | 759 | 831 | 877 | 932 | 916 | 1,284 | 1,927 | 2,679 | 3,422 | 4,333 | 4,799 |
| Borrowings | 362 | 258 | 217 | 802 | 813 | 952 | 826 | 723 | 884 | 1,627 | 2,428 | 5,858 | 6,075 |
| Other Liabilities | 241 | 424 | 468 | 692 | 746 | 813 | 833 | 931 | 1,155 | 1,123 | 1,216 | 2,088 | 2,289 |
| Total Liabilities | 1,371 | 1,557 | 1,648 | 2,529 | 2,640 | 2,901 | 2,779 | 3,143 | 4,170 | 5,633 | 7,271 | 12,482 | 13,367 |
| Fixed Assets | 913 | 1,054 | 1,082 | 1,848 | 1,838 | 2,092 | 1,961 | 1,980 | 2,336 | 2,651 | 4,266 | 7,796 | 8,046 |
| CWIP | 20 | 14 | 53 | 35 | 56 | 12 | 20 | 67 | 259 | 514 | 86 | 292 | 328 |
| Investments | 52 | 87 | 96 | 9 | 17 | 86 | 120 | 132 | 252 | 844 | 1,084 | 573 | 1,242 |
| Other Assets | 385 | 402 | 417 | 637 | 729 | 711 | 678 | 964 | 1,323 | 1,624 | 1,835 | 3,822 | 3,752 |
| Total Assets | 1,371 | 1,557 | 1,648 | 2,529 | 2,640 | 2,901 | 2,779 | 3,143 | 4,170 | 5,633 | 7,271 | 12,482 | 13,367 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 77 | 174 | 219 | 182 | 279 | 443 | 304 | 485 | 1,085 | 1,067 | 986 | 1,621 |
| Investing | −223 | −150 | −146 | −520 | −162 | −189 | −113 | −267 | −1,176 | −1,458 | −1,325 | −3,648 |
| Financing | 140 | 18 | −45 | 315 | −27 | −247 | −194 | −159 | 88 | 488 | 544 | 2,340 |
| Net Cash Flow | −6 | 42 | 28 | −22 | 89 | 7 | −2 | 59 | −4 | 97 | 205 | 313 |
| Free Cash Flow | −15 | 86 | 85 | −20 | 129 | 329 | 235 | 235 | 563 | 99 | −93 | 753 |
| CFO/EBITDA | 78 | 116 | 108 | 100 | 113 | 117 | 133 | 83 | 119 | 99 | 86 | 108 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 38 | 34 | 30 | 45 | 34 | 31 | 39 | 43 | 35 | 31 | 37 | 30 |
| Inventory Days | 56 | 48 | 45 | 56 | 48 | 35 | 32 | 30 | 31 | 44 | 40 | 42 |
| Days Payable | 146 | 152 | 173 | 200 | 177 | 177 | 221 | 180 | 224 | 214 | 185 | 248 |
| Cash Conversion Cycle | −51 | −70 | −98 | −100 | −95 | −111 | −150 | −108 | −158 | −138 | −108 | −176 |
| Working Capital Days | −30 | −12 | −11 | −10 | −10 | −22 | −38 | −16 | −25 | −30 | −17 | −19 |
| ROCE % | 7% | 9% | 14% | 9% | 9% | 14% | 2% | 25% | 32% | 26% | 21% | 16% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Narayana Hrudayalaya insights
62 extracted metrics across FY11–FY27.
Documents
- Q2 FY27 concall · Nov 2026Transcript PPT Recording
- Q2 FY27 concall · Oct 2026PPT
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q1 FY27 concall · Jul 2026PPT
- Q4 FY26 concall · Jun 2026Transcript PPT Recording
- 24 Mar 2026
- 19 Jan 2026
- 10 Nov 2025
- 20 Jan 2025
- 2 Feb 2024
- 20 Nov 2026
- General announcements 17 Nov 2026
- General announcements 17 Nov 2026
- General announcements 5 Nov 2026
Frequently Asked Questions about Narayana Hrudayalaya
What does Narayana Hrudayalaya Ltd do?
Where is Narayana Hrudayalaya Ltd (NH) listed?
Which sector does Narayana Hrudayalaya Ltd belong to?
What is the market capitalisation of Narayana Hrudayalaya Ltd?
What is the PE ratio of Narayana Hrudayalaya Ltd?
What is the 52-week high and low of Narayana Hrudayalaya Ltd?
Does Narayana Hrudayalaya Ltd pay dividends?
What is the Return on Equity (ROE) of Narayana Hrudayalaya Ltd?
Company Information
Narayana Hrudayalaya Ltd is engaged in providing economical healthcare services. It has a network of multispecialty and super specialty hospitals spread across multiple locations.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NH.md for Narayana Hrudayalaya Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.